Tag: apremilast

Apremilast is an orally administered small molecule approved for the treatment of immune-mediated inflammatory conditions. It is classified as a selective phosphodiesterase 4 (PDE4) inhibitor, with anti-inflammatory properties beneficial in conditions such as psoriatic arthritis (PsA), moderate to severe plaque psoriasis, and oral ulcers associated with Behçet’s disease. Indications Apremilast is FDA-approved for the following…